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ABSTRACT

SPROUTY2 DEFICIENCY IN MICE LEADS TO
THE DEVELOPMENT OF ACHALASIA

Sprouty 2 (Spry2), one of the four mammalian Spry family members, is a
negative feedback regulator of many receptor tyrosine kinases (RTKs) signaling
including Met. It fine-tunes RTKs signaling through multiple levels of regulations
starting from RTK itself to several downstream molecules that are crucial for signal
transduction. To understand what role Spry2 might play during developmental
processes, we created a Spry2 conventional knockout mouse in which Spry2
expression is replaced by enhanced green fluorescent protein (EGFP) reporter. Spry2
appears to be expressed in mouse embryo and in many adult tissues, and Spry2deficient mice have smaller body size and shorter lifespan. Pathologically, we
observed that Spry2 deficiency results in impaired relaxation of the lower esophageal
sphincter and mega-esophagus, a condition known as achalasia, which is likely due to
malfunction of the innervated neurons where Spry2 is expressed. The Spry2-deficient
mice may serve as a useful animal model for achalasia. Currently, we are
investigating how loss of Spry2 leads to achalasia and whether the Met pathway plays
a role in the development of this phenotype.
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CHAPTER I

INTRODUCTION

Intracellular signaling is an intensely studied topic in current cell and
molecular biology research. The flow of information from the outside of the cell to
the inside and the communication among the cellular components has revealed many
fascinating discoveries, but much still remains unknown about the specifics of these
communication pathways. One group of cellular receptors that transfers signals
across the cell membrane is the receptor tyrosine kinases (RTKs). These
transmembrane proteins play important roles in processes such as development and
cancer progression; for example, RTKs have been shown to be integral in the
functions of cell migration and proliferation, processes necessary in both a developing
embryo and in cancer (Schlessinger, 2000). The pathways initiated by the receptors
are regulated by a host of proteins designed to potentiate or inhibit the pathway and
thereby allow close regulation of a variety of outcomes from a single receptor.
One of these regulatory proteins was discovered to be a crucial inhibitor of
tracheal branching during Drosophila embryonic development. Excessive branching
of the trachea occurs when the gene for this protein is lost, so it was given the name
Sprouty (Spry) (Hacohen et al., 1998). Spry presence among higher organisms has
since been shown to be wide-spread, as homologous genes have been found in
chickens (Chambers and Mason, 2000), frogs (Nutt et al., 2001), mice (Tefft et al.,
1999), and humans (Minowada et al., 1999). Tracheal branching in Drosophila is
1

normally regulated by fibroblast growth factor receptor (FGFR) signaling, so
excessive branching in the absence of Spry gene provided the first evidence that Spry
negatively regulates RTK signaling (Hacohen et al., 1998). Negative feedback
inhibition of a signaling pathway involves the transcription of a protein that limits the
same pathway that led to its own transcription. Spry has been shown to be a negative
feedback regulator of multiple RTKs including epidermal growth factor receptor
(EGFR), FGFR, and hepatocyte growth factor receptor (HGFR, also known as Met),
whose ligands can induce Spry gene expression (Hanafusa et al., 2002; Reich et al.,
1999; Ozaki et al., 2001; Hacohen et al., 1998; Lee et al., 2004). Spry fine-tunes
RTKs signaling input in a timely manner, thereby influencing the signaling output as
manifested by changes in cellular activities such as cell proliferation, migration, etc.
(Kim and Bar-Sagi, 2004).
The mitogen activated protein kinase (MAP kinase) pathway is a chain of
protein-protein interactions by which the signal that was passed through the cell
membrane is propagated, and terminates in regulation of gene transcription.
Following the conformational change that occurs upon ligand binding, growth factor
receptor-bound protein 2 (Grb2) is able to interact with the receptor as an adaptor
protein, recruiting the guanine nucleotide exchange factor son-of-sevenless (Sos) to
the cell membrane. The small GPTase Ras can then interact with the Grb2-Sos
complex, changing from the GDP to GTP conformation and thereby becoming
activated. Activated Ras binds and activates Raf, a serine-threonine protein kinase,
which subsequently activates a series of kinases eventually leading to phosphorylation
of a protein such as extracellular signal-regulated kinase (ERK) which translocates to
the nucleus and regulates transcription factors for genes leading to cell growth and
differentiation (Molina and Adjei, 2006).
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Spry proteins can exert multiple levels of regulation on RTK signaling,
starting from the receptor itself to several downstream signaling molecules (Kim and
Bar-Sagi, 2004). One way Spry proteins inhibit Ras/MAP kinase pathway is by
sequestering Grb2 so it cannot mediate the binding of Sos to the RTK, a step
necessary for propagating the signal (Gross et al., 2001; Hanafusa et al., 2002). Sprys
also bind to the protein kinase Raf through its conserved cysteine-rich domain,
thereby inhibiting the activation of Raf and downstream ERK (Kim and Bar-Sagi,
2004). Spry becomes inactivated when its tyrosine residues become dephosphorylated
by Shp2 phosphatase (Hanafusa et al., 2004). This leads to disassociation of Spry
from Grb2 and releases Spry-mediated signal inhibition (Hanafusa et al., 2004).
Although Spry proteins seem to be general RTK inhibitors, the mode of Spry
action on different RTKs does not appear to be exactly the same. For instance, FGF
signaling is down-regulated by Spry2 while EGF signaling does not appear to be as
greatly affected (Rubin et al., 2005). One method of down-regulating a signaling
pathway is by marking components of the pathway for degradation by the
proteasome. This marking is performed by the family of E3 ubiquitin ligases, a
prominent member of which is c-Cbl. Spry proteins have also been found to increase
MAP kinase signaling induced by EGF and this increase is likely due to the ability of
Spry to sequester c-Cbl (Egan et al., 2002). Following phosphorylation, Spry can
interact with the Src-homology 2-like domain of c-Cbl and block c-Cbl’s binding to
EGFR, thus preventing EGFR ubiquitination and degradation (Egan et al., 2002; Fong
et al., 2003). This is not the case in FGF-induced signal transduction as Spry shows
no protection against FGFR ubiquitination (Fong et al., 2003). It has been suggested
that the difference between FGF and EGF signaling is most likely due to the ability of
FGFR but not EGFR to phosphorylate certain Spry carboxy-terminal tyrosine residues
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necessary for full inhibitory function (Rubin et al., 2005). This selective
phosphorylation may be a key to the extent Spry plays in regulating RTK signaling
originating from different receptors. The ability for receptors to target specific
tyrosines on the Spry proteins allows a single Spry protein enough versatility to
display a variety of responses, depending on which receptor initiates its
phosphorylation.
There are four members in the mammalian Spry family. Two conserved
regions among Spry protein family members account for their functions: a carboxyterminal cysteine rich domain is responsible for translocation of Spry from its prestimulated location in the cytosol to the post-stimulated location at the plasma
membrane (Lo et al., 2004; Lim et al., 2002). Phosphorylation of an amino-terminal
conserved tyrosine upon growth factor stimulation is crucial for Sprys to inhibit RTKRas-MAP kinase signaling cascade (Hanafusa et al., 2002; Gross et al., 2001; Kim
and Bar-Sagi, 2004).
One method of determining the role of a gene is to overexpress it in vitro or in
vivo. Abnormalities that arise in the over-expression tissue often provide an indication
of the gene’s function. Chick Spry over-expression results in stunting of chick limb
outgrowth by preventing proper bone formation (Minowada et al., 1999). Overexpression of the mouse Spry2 protein in vitro results in decreased cell proliferation,
migration, and invasion, as well as accumulation of cells at cell cycle phase G2/M
(Lee et al., 2004). Endogenous levels of Spry1 and Spry2 proteins negatively regulate
proliferation, differentiation, and anchorage-independent cell growth (Gross et al.,
2001), while promoting cell adhesion and spreading (Lee et al., 2004).
One common means to identify the effect a gene has on development is the
creation of a knockout mouse in which the gene of interest is removed and the
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development of the mouse is followed. Anomalies from standard development
indicate the deleted gene may be influential in the development of the system that
produced the difference observed. Spry1 knockout mice suffer from a ureteric bud
defect that is attributed to loss of Spry1 in the Wolffian duct during embryogenesis,
leading to multiple ureters and epithelial cysts on the kidneys (Basson et al., 2005).
Spry2 knockout mice have also been created and are described in the discussion
section. There have been no reports of Spry3 knockout mice. Spry4 knockout mice
exhibit lower body weights than wild type mice, exhibit polysyndactyly, and have
mandible defects (Taniguchi et al., 2007).
Spry2 has been shown to be induced in leiomyosarcoma cells by hepatocyte
growth factor (HGF) and acts as a negative feedback inhibitor of the Met pathway
(Lee et al., 2004) which is involved in both embryogenesis and tumorgenesis
(Birchmeier et al., 2003). This paper also showed that overexpression of Spry2 leads
to inhibition of HGF-induced AKT and ERK signaling, as AKT phosphorylation was
completely abolished and the duration of ERK phosphorylation was reduced. Cell
proliferation and invasion were also inhibited when Spry2 was overexpressed (Lee et
al., 2004). These attributes are characteristic of tumor suppressor genes, and Lee et al.
were the first to suggest that Spry2 is a tumor suppressor gene.
Previously published data and results within our lab led us to ask questions
related to the role Spr2 plays in the mouse. What happens in vivo when regulation of
the RTKs by Spry2 is lost? Will mice without Spry2 develop tumors more quickly
than mice with normal Spry2 levels? What happens to mouse development when
Spry2 is lost?
We wanted to determine what role Spry2 might play during normal
development; we generated a Spry2 knockout mouse in which Spry2 alleles are

5

replaced by an enhanced green fluorescent protein (EGFP) reporter using a
conventional gene targeting technology. In this mouse model we see evidence for
Spry2 expression in several embryonic and adult tissues as indicated by EGFP
fluorescence. Pathologically, Spry2-deficient mice display an enlarged esophagus and
much smaller body size as well as a shorter lifespan than wild type and heterozygous
littermates, likely due to developmental/functional defect in the lower esophageal
sphincter which fails in relaxation or is hypercontractile, a condition known as
achalasia.
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CHAPTER II

RESULTS

To investigate the role of Spry2 during mouse development, we created Spry2deficient mice using conventional gene knockout techniques. The entire coding region
of Spry2 was replaced with an EGFP/PGK-Neo cassette, leaving EGFP expression
under the control of endogenous Spry2 promoter (Figure 1A). The expected
homologous recombination of Spry2 alleles was confirmed by Southern blot analysis
and PCR genotyping using genomic DNAs derived from Spry2 wild type,
heterozygous and homozygous mice (Figure 1B).
We first examined the expression of Spry2 in various tissues including brain,
lung, and kidney of wild type, heterozygous, and Spry2 homozygous mice by reverse
transcriptase PCR (RT-PCR). Spry2 displays highest expression in the brain, and
moderate expression in the lung and kidney of Spry2 wild type mice (Figure 2A). No
Spry2 expression was detected in the tissues derived from Spry2-/- mice, indicating a
complete Spry2 knock-out (Figure 2A). This was also confirmed by the detection of
EGFP in tissues derived from Spry2+/- and Spry2-/- mice but not Spry2+/+ mice either
by RT-PCR (Figure 2A) or western blot analysis (Figure 2B). DNA, RNA, and
protein results all indicate accurate homologous recombination in the Spry2 alleles.
Mouse embryo and adult tissues were also examined under a fluorescence
microscope to determine the expression sites of Spry2, as seen by EGFP reporter
fluorescence in the Spry2-deficient animal. Spry2-/- embryos show strong fluorescence
in the developing ear and limbs, whereas Spry2+/+ embryos show only background
fluorescence (Figure 3A). Strong EGFP fluorescence was also observed from Spry2-/-
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adult brain, while moderate fluorescence was observed from lung, heart, and kidney
of three-month old Spry2-/- mice (Figure 3B). These data are consistent with the
results obtained from RT-PCR and western blot analysis (Figure 2).
Spry2 wild type, heterozygous and homozygous mice were born in the
expected Mendelian ratio, indicating no embryonic lethality due to Spry2 deficiency.
There is no obvious difference in littermate sizes at birth, but later on Spry2-/- mice
appear to be smaller than their wild type and heterozygous littermates, indicating
growth retardation is likely a result of a postnatal defect (Figure 4A). The average
body weight of the Spry2-/- mice was only two-thirds of the Spry2+/+ and Spry2+/mice (Figure 4A). Upon gross examination, the most obvious difference that we
observed was the appearance of the esophagus (Figure 4B). While other organs
appear proportional to the body size, Spry2-/- mice have a megaesophagus with an
average diameter more than twice as large as wild type or heterozygous littermates
(Figure 4B). The increased diameter extends down to, but does not appear to include,
the lower esophageal sphincter (LES). Longitudinal sections through the LES and
adjoining esophagus reveal an enlarged lumen and dilated wall, while the LES
appears to be in a contractile state (Figure 4C), mimicking a pathological condition
known as achalasia in humans. This phenotype is likely due to a blockage between the
esophagus and stomach resulted from either nonrelaxation or hypercontraction of the
LES. Food and water cannot pass properly through the LES into the stomach due to
the defect, and as a result the Spry2-deficient mice are malnourished, appear skinny,
and are short-living. There is an inverse correlation between body weight and
esophagus size (Figure 4A and 4B).
When examining the location of Spry2 expression in the Spry2-/- esophagi
under a fluorescent microscope, we observed a bright EGFP fluorescence, indicating
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of Spry2 expression, along the longitudinal nervous tissues of the esophagus running
to the LES region (Figure 4D). This suggests that a potential defect in the neuronal
tissues innervating the LES may result in achalasia in the Spry2-/- mice.
To determine if the esophageal phenotype is due to an unregulated Met
signaling in neuronal tissues, we then asked if eliminating Met activity will rescue or
alleviate the Spry2-deficient phenotype. Selective knockout of genes in specific
tissues can be obtained using the cre-lox conditional knockout system (Sternberg and
Hamilton, 1981; Nagy, 2000) in which regions of DNA flanked by LoxP sites can be
deleted only in tissues expressing the cre enzyme. Only one copy of cre recombinase
(cretg/-) is necessary and sufficient to excise any regions flanked by LoxP sites. Since
complete knockout of Met is embryonically lethal (Bladt et al., 1995), we
conditionally knocked out the Met allele in neuronal tissues by crossing MetLoxP/LoxP
mice (Borowiak et al., 2004) to nestin-cretg/- mice in which cre recombinase is
specifically expressed in the neuronal tissues under the control of nestin gene
promoter (Burns et al., 2007). Using the mating scheme outlined in Figure 5, we
aimed to obtain animals with MetLoxP/LoxP; nestin-cretg/-; Spry2-/- genotype to achieve
Spry2-deficiency in conjunction with Met alleles specifically knocked out in neuronal
tissues. However, no animals of this genotype have been observed thus far.
To determine how loss of Spry2 affects RTK signal transduction in vitro, we
established mouse embryonic fibroblast (MEF) cell lines from Spry2 wild type,
heterozygous, and homozygous embryos. A more robust ERK phosphorylation was
observed in Spry2-/- MEF cells upon EGF stimulation, compared to that in the
Spry2+/+ and Spry2+/- cells (Figure 6), indicating that releasing negative regulation
from Spry2 may enhance the RTK signaling.
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CHAPTER III

DISCUSSION

While most studies have focused on in vitro analysis of the pathways Spry2
affects (Lee et al., 2004; Chambers and Mason, 2000; Hanafusa et al., 2002), we
aimed to examine the role of Spry2 in vivo and to determine how loss of Spry2 may
affect mouse development. In this study we created and characterized a Spry2
knockout mouse in which the Spry2 gene is replaced by an EGFP reporter. We
observed that loss of Spry2 results in a postnatal defect in the esophagus as
manifested by a severely dilated and enlarged esophagus and nonrelaxation or
hypercontraction of the lower esophageal sphincter (LES) (Figure 4), a condition
known as achalasia in humans (Richter, 2010). Spry2 appears to be expressed in the
enteric nerve tissues of the esophagus, especially around the LES, as evidenced by the
EGFP fluorescence (Figure 4D). Identification of endogenous Spry2 presence in the
esophageal neuronal tissue suggests a possible role for Spry2 in controlling sphincter
function. The LES appears to be an important location of Spry2 activity, which is
consistent with published data showing LES contraction in Spry2 null mice to be five
times as strong as wild type mice (Taketomi et al., 2005).
Spry2 is the most closely studied isoform among all Spry family members for
its role in cancer (Lo et al., 2004; McKie et al., 2005; Fong et al., 2006). Even though
Spry2 is highly expressed in the brain and moderate in tissues such as lung and kidney
(Figure 3), we observed no spontaneous tumor formation in Spry2-deficient mice,
suggesting that loss of Spry2 alone is not sufficient for tumorigenesis. Other labs
publishing Spry2 knockout mice phenotypes have not described tumor formation as a

10

result of Spry2 loss either. It is also possible that other Spry family members may be
compensating somewhat for Spry2 loss, preventing or suppressing tumor formation
while other phenotypes of Spry2 deficiency are still visible. It remains to be seen if
the diffenential phosphorylation of Spry2 residues in response to various growth
factors plays a role in tumor formation.
Two other research groups have reported phenotypes lacking Spry2 in mice:
one described a severe hearing impairment (Shim et al., 2005), and the other showed
an esophageal phenotype similar to the one we observed (Taketomi et al., 2005). The
hearing impairment defect in Spry2-deficient mice has been attributed to excessive
FGF signaling which leads to the development of an extra pillar cell in the inner ear
(Shim et al., 2005). Glial cell derived neurotrophic factor (GDNF) signaling was
reported to be responsible for developing Spry2-deficient esophageal phenotype
(Taketomi et al., 2005). In the latter case, the authors conclude that loss of Spry2
results in enteric nerve hyperplasia, based on counting immunostained neurons from
mouse esophagus and colon (Taketomi et al., 2005). Injection of neutralizing antibody
against GDNF or an antagonist of Ret (the receptor tysosine kinase for the GDNF
ligand) into neonatal Spry2-/- mice alleviated some of the esophageal phenotype
(Taketomi et al., 2005), although the animals were followed for only a short time
window that may not have taken into account the incomplete penetrance we see in our
Spry2-deficient animals. Ret germline inactivating mutations are the cause of about
half the cases of a human condition known as Hirschsprung’s disease. This condition
is manifested by megacolon due to a defect in the enteric innervation known as
intestinal aganglionosis (Arighi et al., 2005). It seems that the esophagus is spared
from defect due to Ret deficiency, as knocking out Ret in mice causes intestinal
aganglionosis but only partially affecting enteric innervation in the esophagus
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(Durbec et al., 1996). Yet, another report showed that neural cells in the esophagus
are Ret-dependent (Yan et al., 2004). There seems to be no direct evidence showing
that the Spry2-deficient esophageal phenotype is caused by GDNF-Ret pathway. A
direct approach to test this hypothesis would be to cross Spry2 knockout mice with
Ret-deficient mice and determine if loss of Ret activity rescues achalasia resulted
from Spry2 deficiency.
Interestingly, it has also been reported that GDNF can induce Met
phosphorylation in Ret-deficient cells (Popsueva et al., 2003), suggesting that Met
may mediate Ret-independent GDNF signaling in certain cell contexts. This option of
GDNF signaling through the Met receptor opens the possibility of crosstalk between
the HGF-Met and GDNF-Ret pathways. If this is the case in Spry2-deficient mice, the
results of the anti-GDNF experiment in the paper by Taketomi et al. may have been
dependent on Met signaling also.
The Met gene codes for an RTK that has been shown to play an important role
both in embryonic development and in cancer metastasis. Met has a key function in
placenta formation, liver development, myogenic precursor cell spread, and
integration of the nervous system (for reviews, see Birchmeier et al., 2003; Trusolino
et al., 2010). HGF binds the Met receptor and initiates several signaling pathways that
lead to proliferation, migration, invasion, or other cellular outcomes (Birchmeier et
al., 2003).
Since Spry2 is a negative feedback regulator of HGF-Met signaling pathway,
we asked if Met plays a role in the development of achalasia phenotype in Spry2deficient mice. Met knock-in (Metki) mouse lines in which a cassette derived from Met
cDNA was introduced into the Met locus have been produced (Graveel et al., 2005).
The mice with this insertion but lacking Met activation mutations developed severe
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megaesophagus, however various constitutive activating mutations in the cassette
rescued the phenotype (unpublished results). Although it could be predicted that loss
of Spry2 in the presence of hyperphosphorylated active Met would enhance the
esophageal phenotype, crossing our Spry2 line to a line with one of these activating
mutations did not significantly alter the esophageal diameter or the lifespan of the
Spry2-deficient mice (unpublished data). Crossing Spry2-deficient mice to the Metki
line with no mutations should answer the question if Metki/ki; Spry2-/- mice have an
even larger esophagus or if they are even viable at all.
HGF is a chemoattractant for motor neurons during development and guides
neuron outgrowth (Maina and Klein, 1999). HGF also patterns the axonal outgrowth,
and HGF mutant mice have been found to have defective motor axon growth (Miana
et al., 2001). In addition, Met has been reported to play an important role in axonal
development, with Met mutant mice developing shorter nerves that have fewer
branching points than wild type mice (Miana et al., 1997). Anti-HGF antibodies can
stunt the differentiation of sympathetic neurons, and survival and growth of these
neurons are significantly enhanced with HGF (Miana et al., 1998).
Two major pieces of evidence pointed us toward examining the role of Spry2
in mouse development: 1) HGF has been shown to upregulate Spry2 expression (Lee
et al., 2004), and 2) the HGF-Met pathway is crucial in neuronal development (Miana
et al., 1997; Miana et al., 1998; Miana et al., 2001). Given the Met signaling
importance in neuronal development and its negative regulation by Spry2, we
speculated that Met might play a role in the development of achalasia in Spry2-/- mice.
Therefore, we hypothesized that Met signaling is responsible for the migration of
neural crest cells into the esophagus. Absence of Spry2 leads to enhanced Met
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signaling in the neural crest cells, likely leading to hyperganglionosis in the
esophagus.
To test our hypothesis, we asked if eliminating Met activity rescues the
esophageal phenotype developed by the Spry2-deficient mice. If Met is the driver of
this phenotype, eliminating Met should restore the normal esophageal phenotype.
Since complete knockout of either Met or HGF results in embryonic lethality (Bladt et
al., 1995; Schmidt et al., 1995; Uehara et al., 1995), we took an approach to
conditionally knockout Met in the neuronal tissues by crossing Met-flox mice
(Borowiak et al., 2004) with nestin-cre transgenic mice in the absence of Spry2 (see
Figure 5 for breeding scheme). However, we have not yet obtained any mice
exhibiting either a MetLoxP/+;Nestin- cretg/-; Spry2-/- or MetLoxP/LoxP;Nestin- cretg/-;
Spry2-/- genotype. Albumin-cre mice express cre recombinase in the liver (Postic et
al., 1999), and crossing these mice with MetLoxP/LoxP, Spry2-/- mice can produce a
MetLoxP/LoxP; albumin-cretg/-; Spry2-/- mouse, ruling out a possible background effect
due to the cre mouse strain. MetLoxP/LoxP;Nestin- cretg/-; Spry2+/+ mice are also viable,
indicating that the loss of Met in the neuronal tissue alone is not lethal. Two
possibilities may account for the lack of the two mouse genotypes: 1) there have not
been enough pups born to see the genotypes we are seeking, or 2) those two
genotypes are embryonically lethal. We are currently investigating these possibilities.
Taken together, we show that Spry2 is expressed in the enteric nerve
innervations of the esophagus and its deficiency results in the development of
esophageal achalasia. We are aiming to gain further insight into how this condition is
developed in the absence of Spry2 and whether Met plays a role in its onset. The
Spry2 knockout mouse can be a useful model for understanding the underlying
mechanism of achalasia and for developing therapies for this condition.
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CHAPTER IV

MATERIALS AND METHODS

Generation of Spry2 Knockout Mouse
To construct a Spry2 targeting vector as shown in (Figure 1A), a 2-kb genomic
fragment (including partial intron 1 and partial exon 2) and a 4.6-kb genomic
fragment downstream of exon 2 were inserted into the pPNT vector (Tybulewicz et
al., 1991) ahead of and behind an EGFP-PGK-NEO cassette, respectively. In the
resulted vector, the EGFP reporter uses the ATG codon from Spry2 gene as its
starting codon. Once homologous recombination takes place, the entire coding region
of Spry2 is replaced by the EGFP-PGK-NEO cassette, and the EGFP reporter is under
the control of Spry2 promoter for its expression. To generate ES cells carrying the
Spry2+/- genotype, ES cells were electroporated with a linearized targeting vector and
selected with neomycin. Two established Spry2+/- ES clones were used to generate
Spry2 knockout mice. Successive homologous recombination was confirmed by
Western Blot analysis and PCR genotyping as detailed below.

Southern Blot Analysis
Mouse tails were clipped at weaning and were submitted to automatic DNA
extraction by an AutoGenPrep 960 machine (AutoGen). DNA was then digested with
restriction enzymes NdeI and HindIII, separated via electrophoresis, and transferred to
a Hybond XL membrane. The Sy2-5’ probe (Figure 1A) was radiolabeled with 32P,
hybridized with the membrane, and detected on a Kodak x-ray film.
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PCR Genotyping
For PCR genotyping of Spry2, three primers (P1, P2, and P3) were used in a
mixed reaction to distinguish wild type and mutant alleles (Figure 1A). The forward
primer P1 (5’-GACTTGACCGATACGTTGTAGG-3’) is common to both wild type
and mutant alleles. The reverse primer P2 (5’-ATCAGGTCTTGGCAGTGTGTTC3’) is specific for wild type allele, while P3 (5’-ATGAACTTCAGGTCAGCTTGC3’) is specific for mutant allele. PCR amplification used an annealing temperature of
58°C and an elongation period of two minutes for 30 cycles. Genotypes were
determined by separating the PCR products on a 1.2 % agarose gel containing
ethidium bromide, followed by visualization under UV light.

Other Mouse Strains
Nestin-cre animals were purchased from Jackson Laboratories (www.jax.org).
Met-flox mice were obtained from Dr. Carmen Birchmeier (Max Delbrück Center for
Molecular Medicine, Germany).

RT-PCR
Brain, lung, and kidney tissues were harvested and homogenized in 4 mL of
TRIzol reagent (Sigma-Aldrich). RNA extraction proceeded according to the TRIzol
protocol. A One-Step RT-PCR Kit (Invitrogen) was employed according to the
manufacturer’s recommendations, using primers as follows: 5’CAGATGTGTTCTAAGCCTGCTG-3’ and 5’-GAGCAACAATCCCTATTACTGC3’ for Spry2; 5'-AAGGACGACGGCAACTACAAG-3' and 5'CGGATCCGCTCGAGCGCCTTAAGATACATTGATGAG-3' for EGFP; 5'TCCAGTATGACTCCACTCACG-3' and 5'-ACAACCTGGTCCTCAGTGTAG-3'
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for GAPDH. PCR products amplified using an annealing temperature of 55 °C and an
elongation time of one minute (30 cycles) were run on a 1 % agarose gel containing
ethidium bromide and visualized under UV light.

Tissue Culture
Mouse Embryonic Fibroblasts (MEFs) were established from day-14
individual embryos and cultured in DMEM (Invitrogen) supplemented with 10% Fetal
Bovine Serum (HyClone) and 1% Penicillin/Streptomycin. Following establishment,
the MEF cells genotypes were determined by PCR.

Western Blot Analysis
Mice were sacrificed and the brain, lung, and kidney of each mouse was
homogenized separately in RIPA buffer [50 mM Tris-HCl, pH 7.4, 1 % NP-40,
0.25 % Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 µg/mL
Aprotinin, 1 µg/mL leupeptin, 1 µg/mL pepstatin, 1 mM Na3VO4, 1 mM NaF,
Complete Protease Inhibitor Tablet (Roche Applied Science)]. Subsequently, samples
were frozen in liquid nitrogen to rupture the cells, thawed at 4 °C, and centrifuged at
13,500 rpm for fifteen minutes.
To collect tissue culture lysates, cells were rinsed with phosphate buffered
saline (PBS) and RIPA was added. Following 15 minute incubation at 4°C, cell debris
was removed by centrifugation at 13,500 rpm for 15 min. Protein lysates were
quantified using the DC Protein Assay (Bio-Rad) according to manufacturer’s
specifications, and diluted to equal concentrations in 2X Laemmli Sample Buffer
(Sigma). Proteins were denatured by boiling for five minutes and then loaded into a
10 % Tris-Glycine PAGE gel (Invitrogen) in equal concentrations. The gel was run at
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125 volts for approximately two hours, and transferred to a PVDF membrane
(Invitrogen) via electrophoresis at 25 volts for two hours. The membrane was blocked
with 5 % dry milk for one hour, and probed overnight at 4 °C with the primary
antibody. Membranes were washed with Tris Buffered Saline with Tween (TBST),
probed with the appropriate anti-rabbit or anti-mouse secondary antibody (Amersham
Biosciences RPN2108) for one hour at room temperature, and then washed again.
Blots were developed on X-ray film using an Amersham Biosciences ECL kit
(RPN2108). The primary antibodies used were: GFP (AbCam ab290, 1:1000),
phospho-ERK (Cell Signaling #9101S, 1:1000), and β-actin AC-17 (Sigma-Aldrich
A1978, 1:10,000).

Paraffin Embedded Tissue Slide Preparation
Tissues were fixed overnight in formalin, embedded in paraffin wax, cut in 5
µm sections, and stained with hematoxylin and eosin.

Fluorescence Microscopy
Ectopic Spry2 expression was investigated by examining EGFP fluorescence
in embryo and adult tissues. Organs extracted from sacrificed mice or whole embryos
(day-15 old) were directly viewed under UV illumination using a Leica MZ FLIII
fluorescence stereomicroscope for EGFP fluorescence. The esophagus was opened
longitudinally and splayed for examination under a Zeiss LSM510 META Confocal
Microscope.
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Figure 1. Targeted disruption of mouse Spry2 wild type alleles. (A) Diagram of the
gene targeting vector for the Spry2 knockout mouse, and the genomic structures of the
wild type (WT) and mutant alleles, respectively. After homologous recombination,
the entire coding region within exon 2 (E2) was deleted and replaced with a cassette
containing EGFP and PKG-NEO. The EGFP sequence was linked to the leftover short
fragment of E2 and its expression is under the control of Spry2 gene promoter. The
indicated restriction enzyme sites are: B, BamH I; E, EcoR I; H, Hind III; N, Nde I.
(B). Determining Spry2 WT and mutant alleles by Southern Blot analysis and PCR
genotyping. The mouse genomic DNA was digested by Nde I and Hind III, and the
blot was hybridized with 32P-labeled Sy2-5’ probe. A 9.2 kb WT band and an 8.2 kb
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mutant band were detected accordingly. PCR genotyping was performed using primer
pair P1-P2 for WT allele and P1-P3 for mutant allele.
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Figure 2. EGFP replaces Spry2 expression in Spry2 heterozygous and homozygous
mice. (A) Reverse Transcriptase-PCR detection of Spry2 and EGFP in mouse tissues.
Total RNA was prepared from brain, lung, and kidney derived from Spry2+/+, Spry2+/-,
and Spry2-/- mice. RT-PCR was performed using primer pairs specifically for mouse
Spry2 and EGFP. GAPDH was also amplified as an internal control. (B) Detection of
EGFP protein in Spry2 heterozygous and homozygous mouse tissues. Whole protein
extract was prepared from the indicated mouse tissues, subjected to Western Blot
analysis, and probed with anti-GFP and anti-β-actin antibodies.
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Figure 3. Visualization of Spry2 expression in embryo and adult tissues of Spry2deficient mice revealed by EGFP fluorescence. (A) Spry2+/+ and Spry2-/- embryos at
embryonic day 15. Green fluorescence represents EGFP expression. (B) Adult brains,
lungs, kidneys and hearts derived from three months old Spry2+/+ and Spry2-/- mice
were visualized under a Leica FLUO III microscope.
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Figure 4. Spry2 deficiency results in growth retardation and mega-esophagus in
Spry2-/-mice. (A) Upper: Appearances of three months old Spry2+/+, Spry2+/- and
Spry2-/- mice. Spry2-/- mice display a much smaller body size than the Spry2+/+ and
Spry2+/- littermates of the same age. Lower: Average mouse mass as measured at the
time of necropsy. (B) Upper: Gross anatomy of esophagus and stomach derived from
Spry2+/+, Spry2+/- and Spry2-/- mice, respectively. The Spry2-/- mouse esophagus is
twice as large in diameter as that of wild type or heterozygous littermates. The bottom
part of the mutant esophagus at the lower esophageal sphincter (LES) region does not
appear enlarged. Lower: Average esophagus diameter at the time of necropsy. n.s. =
no significant difference, *** = p < 0.001 by Student’s T-test, Spry2+/+ n=26, Spry2+/n=58, Spry2-/- n=96, error bars = standard deviation (C) Hematoxylin and eosin
staining of the Spry2-/- mutant esophagus revealed enlarged lumen space with marked
hyperkeratosis. The esophagus-stomach junction does not appear to be enlarged. (D)
Left panel shows gross visualization of EGFP fluorescence in the esophagus derived
from 3 months old Spry2+/+ and Spry2-/- mice. Right panel shows high-power confocal
image of EGFP fluorescence revealing the neuronal network in the mutant esophagus.
Arrowhead indicates the location of LES; arrows indicate nerve tissues with strong
fluorescence across the mutant esophagus and especially around the LES region.
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Figure 5. Mating scheme for conditional knockout of Met in the neuronal tissues of
Spry2-deficient mice. Spry2+/- mice are crossed to MetloxP/loxP and Nestin-cretg/- mice
to generate MetloxP/loxP;Nestin-cretg/-;Spry2-/- mice for determining the role of Met in
the development of the Spry2-/- esophageal phenotype. Values in parentheses are the
expected percentages of offspring with the indicated genotype.
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Figure 6. Loss of Spry2 causes ERK/MAPK hyperactivation in response to growth
factor stimulation in Spry2-/- MEF cells. MEF cell lines were established from
prenatal Spry2+/+, Spry2+/- and Spry2-/- mouse embryos (day 15). Cells were plated in
6 well dishes, serum starved overnight, and then stimulated with EGF (50 ng/mL) for
the indicated times. Whole cell lysates were prepared and subjected to Western Blot
analyses. The blots were probed with phospho-p44/42 MAPK (p-ERK), GFP, and βactin antibodies sequentially.

34

